Clinical trial NCT00140140: A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
Official title: An Open-Label Phase I/II Study of Weekly ABI-007 and Vinorelbine With or Without G-CSF in Patients With Stage IV (Metastatic) Breast Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Stage IV (Metastatic) Breast Cancer
Keywords: Breast cancer
Lead sponsor: Celgene
Sponsor class: INDUSTRY
First posted: 2005-09-01
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to: 1) determine the optimal tolerated dose of ABI-007 and vinorelbine, given concurrently on a weekly basis, in the absence of planned growth factor support with granulocyte colony-stimulating factor (G-CSF) (Patients with HER-2/neu positive disease may receive Herceptin, and 2) determine the optimal tolerated dose of ABI-007 and vinorelbine, given concurrently on a weekly basis, in the presence of planned growth factor support with G-CSF.


Eligibility criteria: Inclusion Criteria:

* Patient has microscopically confirmed invasive breast carcinoma with clinical and/or radiographic evidence of stage 4 disease. If diagnosis is based on pleural effusion, positive cytology must be confirmed.
* Patient has had no prior chemotherapy for Stage 4 disease (hormone therapy is permitted). Prior adjuvant paclitaxel by 3-hour infusion is permitted, if there is no residual neuropathy. Prior adjuvant docetaxel on an every 3 week schedule is permitted.
* Disease must be measurable (unidimensional by Response Evaluation Criteria In Solid Tumors (RECIST) criteria) or evaluable (e.g., malignant effusion, marrow involvement). Elevated tumor markers alone are insufficient.
* Age \>18.
* Southwest Oncology Group (SWOG)/Eastern Oncology Group (ECOG) performance status must be \< or =2 at screen and on treatment day one.
* Life expectancy must be estimated at \>16 weeks.
* Prior irradiation is permitted, provided:

  * Does not exceed 25% of the estimated bone marrow volume
  * Measurable/evaluable disease exists outside the radiation field, or progressive disease is documented within the radiation field.
* Informed consent must be obtained prior to registration.
* Patients must be \> 2 weeks from prior surgery; \> 3 weeks from radiation therapy to the pelvis, spine or long bones; \> 3 weeks from prior chemotherapy (\> 6 weeks for mitomycin C or nitrosureas), or \> 2 weeks from prior hormonal therapy.
* All patients must have placement of appropriate central venous access device.
* Tumor HER2/neu expression must be determined prior to study enrollment. Assessment may be by fluorescence in situ hybridization (FISH) assay or by immunohistochemistry (ICC). If determination is intermediate by ICC, FISH must be performed. For enrollment purposes, this phase I study will not discriminate based on HER2 status. However, documentation of patients' HER2 status will be maintained and Herceptin will be prescribed for all HER2 positive patients.

Exclusion Criteria:

* Granulocytes \< 1,500/mm\^3.
* Platelets \< 100,000/mm\^3.
* Hemoglobin \< 9 gm/dl.
* Creatinine \> 2.0 mg/dl.
* Total bilirubin \> 2 mg/dl.
* Visceral crisis characterized by rapidly progressive hepatic or lymphangitic lung metastases.
* Medically unstable as judged by the patient's physician.
* Pregnancy or lactation; failure to employ adequate contraception.
* Uncontrolled central nervous system (CNS) disease.
* Pre-existing Grade ≥ 2 peripheral neuropathy except for abnormalities due to cancer.
* Psychological, familial, sociological or geographical conditions which do not permit weekly medical follow-up and compliance with the study protocol.
* Prior therapy with vinorelbine or prior therapy with a taxane that resulted in neuropathy.

Primary outcomes:
measure: Participants With Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)
timeFrame: up to month 30
measure: Participants With Dose Limiting Toxicities
timeFrame: up to month 1
measure: Percentage of Participants With Discontinued, Delayed or Interrupted Therapy
timeFrame: up to week 129
measure: Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC), White Blood Cell (WBC), Platelet, and Hemoglobin Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
timeFrame: up to week 129 (longest treatment)
measure: Nadir Measurement for Absolute Neutrophil (ANC), White Blood Cell (WBC) and Platelet Count
timeFrame: up to week 129 (longest treatment)
measure: Nadir Measurement for Hemoglobin (Hgb)
timeFrame: up to week 129 (longest treatment)
Secondary outcomes:
measure: Percentage of Participants With Stable Disease for >= 16 Weeks, or Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)
timeFrame: up to month 30
measure: Kaplan Meier Estimate for Time to Disease Progression (TTP)
timeFrame: up to month 30
measure: Kaplan-Meier Estimate for Duration of Response
timeFrame: up to month 30
measure: Kaplan Meier Estimate for Progression-Free Survival (PFS)
timeFrame: up to month 30
measure: Kaplan-Meier Estimates for Participant Survival
timeFrame: up to 39 months
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope Comprehensive Cancer Care Center
state: California
city: Seattle
country: United States
facility: Seattle Cancer Care Alliance
state: Washington
Study officials:
References: